I n clinical trials, aldosterone (Aldo) antagonists decrease cardiovascular mortality by unknown mechanisms. 1, 2 Aldo is a steroid hormone that acts by binding to the mineralocorticoid receptor (MR), a member of the nuclear receptor family of ligand-activated transcription factors. Aldo elevates systemic blood pressure by activating renal MR-dependent gene transcription; therefore, the vascular effects of Aldo have previously been ascribed to renal MR-mediated blood pressure elevation with secondary vascular consequences. 3 However, the reduction in ischemic events in clinical trials of renin-angiotensin-Aldo system antagonism is significantly greater than that expected from the modest decrease in systemic blood pressure in treated patients, 1, 2, 4 suggesting a direct role for vascular MR activation in cardiovascular pathology. The importance of understanding the direct vascular effects of Aldo has recently been highlighted by the failure in clinical trials of the high-density lipoprotein-raising cholesteryl ester transfer protein inhibitor torcetrapib, despite significant improvements in cholesterol profiles, likely due to off-target increases in serum Aldo levels. 5 Post hoc analyses demonstrated a correlation between electrolyte evidence of Aldo excess and increased carotid intimal thickness, coronary atherosclerosis, cardiovascular ischemia, and mortality in torcetrapibtreated patients. 6, 7 Over the past decade, evidence has accumulated for the presence of functional MR in cardiovascular tissues. 8 We have demonstrated that human vascular smooth muscle cells 9 and endothelial cells (EC) 10 express MR capable of regulating vascular specific gene expression and transcriptional programs. We showed further that vascular smooth muscle cell (SMC) MR regulates expression of genes involved in vascular fibrosis and calcification, 9, 11 whereas in EC, MR regulates genes involved in cell adhesion and oxidative stress. 10 The MR can be activated by both Aldo and cortisol (the glucocorticoid receptor ligand); however, hormone specificity is conferred in Aldo-responsive tissues, such as the kidney, by expression of the cortisol-inactivating enzyme 11␤-hydroxysteroid dehydrogenase-2. Although the in vivo ligand for vascular MR is still debated, multiple groups have demonstrated expression and function of 11␤-hydroxysteroid dehydrogenase-2 in human vascular cells and vessels. 9, 10, 12, 13 These data support the idea that human vascular cells contain functional MR capable of directly responding to Aldo by regulating gene expression. We hypothesized that Aldo-regulated genes in blood vessels may play a role in the mechanism of Aldo-enhanced vascular disease. Aldo-regulated genes have been identified by gene expression profiling of kidney and heart cells and tissues 14 -16 ; however, direct MR target genes in intact blood vessels have not been systematically identified.
In animal models, Aldo promotes vascular inflammation, 17 vascular remodeling after injury, 18, 19 and atherosclerosis, 20 although the mechanisms are largely unknown. Although several mRNAs and proteins, including monocyte chemoattractant factor 1, osteopontin, and cyclooxygenase 2, have been shown to be increased in vascular tissues after Aldo infusion into animals, 17, 21 whether these expression changes are due to direct effects of Aldo acting on vascular MR or secondary to MR activation in other tissues, such as the kidney or heart, cannot be determined from these animal studies.
We have recently confirmed in the mouse wire carotid injury model that Aldo enhances vascular remodeling only with the concomitant presence of endothelial damage. 19 This is consistent with other animal studies demonstrating that Aldo, acting via MR, exacerbates vascular injury responses to a variety of conditions that cause endothelial dysfunction, including mechanical EC injury, 18 uninephrectomy/high saltinduced hypertension, 17 or hyperlipidemia-induced vascular damage. 20 To further explore the molecular mechanisms of Aldo-stimulated vascular disease, we now identify the early Aldo-regulated vascular transcriptome, examine the mechanism of direct regulation of vascular gene expression by Aldo, and explore potential novel mechanisms for the synergy between Aldo and endothelial damage in promoting vascular disease. Understanding the molecular mechanism for the synergistic effects of Aldo on vascular disease in the setting of endothelial damage may help explain the beneficial effects of MR antagonists in patients with vascular diseases and may identify novel therapeutic targets to prevent cardiovascular ischemia.
Methods

Animal Studies
Animals were handled in accordance with National Institutes of Health standards, and all procedures were approved by the Tufts Medical Center Institutional Animal Care and Use Committee. Surgical procedures used inhaled isoflurane anesthesia. Male C57BL/6J or endothelial nitric oxide synthase (eNOS) knockout mice 22 were pretreated with spironolactone (20 mg/kg per day) for 5 days to suppress basal MR activation. For gene expression profiling, aortas were treated ex vivo with 100 nmol/L Aldo or vehicle for 2, 4, or 8 hours; RNA was isolated; and 3 pooled biological replicates were performed. For denuded vessel studies, the aorta was opened longitudinally, and the EC was denuded by gently wiping with a cotton swab. See the Supplemental Methods, available online at http://atvb.ahajournals.org, for details and validation of the ex vivo approach.
Human Vessel Studies
Discarded, deidentified human aorta was collected at the time of coronary artery bypass graft surgery with approval from the Tufts Medical Center Institutional Review Board and treated ex vivo with vehicle or spironolactone (1 mol/L) for 18 hours as described. 19 
Cell Culture
Primary mouse aortic SMC (see the Supplemental Methods for culture conditions), pretreated for 24 hours in 10% charcoal stripped serum, were treated for 8 hours with Aldo or vehicle, and total RNA was isolated for quantitative reverse transcription-polymerase chain reaction (QRT-PCR).
RNA Isolation, Microarray Hybridization, and Microarray Data Analysis
Reverse-transcribed aortic RNA was hybridized to Mouse Genome 430A 2.0 microarrays (Affymetrix, Santa Clara, CA) at the Dana Farber Cancer Institute Microarray Core Facility. The data were normalized and analyzed using the GC content Robust Multichip Analysis protocol using the Benjamini and Horchberg adjustment for multiple testing to calculate the adjusted probability values (P Adj ) as described 23 (Supplemental Methods). Complete expression data are available at National Center for Biotechnology Information Gene Expression Omnibus accession no. GSE23566. Genes with highly reproducible (P Adj Յ0.05) Aldo-regulated expression changes of at least 1.5-fold were used in all further analyses. The analysis for Gene Ontology (GO) enrichment was performed using the GO Tree Machine. 24
QRT-PCR
Aortas were treated ex vivo with Aldo (100 nmol/L), cortisol (10 nmol/L), actinomycin D (5 g/mL), cycloheximide (40 g/mL), spironolactone (10 mol/L), eplerenone (50 mol/L), RU485 (Mifepristone, 100 mol/L), Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine, 10 mmol/L), apocynin (4Ј-hydroxy-3Ј-methoxyacetophenone, 600 mmol/L), or N G -methyl-L-arginine acetate (L-NMMA) (4 mmol/L) for 8 hours unless otherwise indicated. After this treatment, RNA was isolated, and QRT-PCR was performed as described. 23 
QRT-PCR Statistical Analysis
QRT-PCR values are reported as meanϮstandard error of the mean. Within-group differences were assessed with 1-factor ANOVA with the Student-Newman-Keuls or Dunn method post test when appropriate. PϽ0.05 was considered significant.
Results
Aldo Directly Regulates Aortic Gene Expression
Aldo-responsive vascular genes were identified by gene expression profiling of RNA from mouse aortas treated ex vivo for 2, 4, and 8 hours with Aldo compared with vehicle (National Center for Biotechnology Information Gene Expression Omnibus accession no. GSE23566). The time points were based on published data demonstrating that after hormone exposure, steroid receptors bind to DNA within 45 to 60 minutes, with detectable changes in gene expression after 2 hours and protein expression after 8 hours. 19, 23, 25 Genes with Aldo-responsive expression changes that were significant in magnitude (Ͼ1.5-fold compared with vehicle) and highly reproducible (P Adj Ͻ0.05) were included in all further analyses. Using these strict criteria, the number of Aldoregulated genes increased over time with 10, 15, and 58 regulated genes at 2, 4, and 8 hours, respectively ( Figure 1A and Supplemental Tables I to III) . Aldo-mediated gene repression predominated in the first 2 hours (70% repressed), whereas gene induction was more prominent at 4 to 8 hours (7% and 14% repressed, respectively, Figure 1A ).
The Aldo-stimulated microarray expression changes were validated by QRT-PCR analysis in independently obtained mouse aorta RNA samples ( Supplemental Table IV ). Nineteen genes were chosen for confirmation on the basis of large-magnitude Aldo-induced changes or interesting roles in vascular biology, and they included both Aldo-stimulated and Aldo-repressed genes and genes with changes at each of the 3 time points. Sixteen upregulated gene expression changes were tested (28% of Aldo-upregulated genes), 14 of which were reproducible in both the magnitude and direction of the change (88%). Three downregulated genes were tested (20% of Aldo-downregulated genes), and although the downregulation was less consistent, 2 of the 3 genes tested decreased at least 25% by Aldo treatment. Overall, 84% of genes tested displayed levels of Aldo regulation by QRT-PCR comparable to those in the global gene profile, thereby confirming, in new aortic samples, the validity of both the microarray technique and the Aldo-stimulated changes in gene expression.
Temporal Pattern of Aldo-Regulated Genes in the Aorta
The temporal pattern of Aldo-regulated genes was explored by analyzing the degree of overlap between gene sets at each time point ( Figure 1B ). The 2-hour Aldo-regulated gene set was distinct from the other time points, as it contained only 1 gene that was also regulated by Aldo at 4 and 8 hours. In contrast, there was significant overlap between genes regulated by Aldo at 4 hours, with 10 of the 15 (67%) genes being persistently Aldo regulated at 8 hours. A third wave of gene expression begins at 8 hours that is distinct from the earlier regulated genes, with 48 of the 58 genes regulated by Aldo at 8 hours being unique. Only 1 Aldo-regulated vascular gene (baculoviral AIP repeat containing-2 [BIRC2], 1.4%) was persistently significantly induced by Aldo over the entire 8-hour time period.
Functions of Aldo-Regulated Vascular Genes
The GO Tree Machine was used to identify specific functional categories based on GO annotation that are significantly overrepresented in the 72 vascular Aldo-regulated genes. Overall, there are 22 overrepresented GO categories in this gene set. The Table lists the 10 categories at the end of each GO tree with their associated genes and the probability value for the overrepresentation of genes in the Aldoregulated vascular gene set compared with randomly generated sets of 72 genes. The overrepresented categories are relevant to the known role of Aldo in regulating oxidative stress (NO-mediated signal transduction), vascular cell proliferation (angiogenesis, negative regulation of progression through cell cycle), and extracellular matrix formation and degradation (integrin-mediated signaling pathway, extracellular matrix, metaloendopeptidase activity), supporting the idea that Aldo-regulated vascular genes may play a role in mineralocorticoid-mediated vascular dysfunction and disease by altering vascular gene expression.
Dose-Response Relationship for Vascular Aldo Gene Regulation
A subset (10%) of highly reproducible Aldo-regulated vascular genes was chosen to further explore the mechanism of Aldo regulation in the vasculature. Six genes were chosen on the basis of their presence in functionally relevant overrepresented GO categories, including placental growth factor (PGF), metallothionein 1 and 2 (MT1, MT2), connective tissue growth factor (CTGF), BIRC2, and serum-and glucocorticoid-regulated kinase (SGK). The seventh gene, FK506 binding protein 51 (FKBP5), was chosen because it is a well-studied steroid-responsive gene in nonvascular cells. 26, 27 The dose-response relationship of Aldo regulation of these genes was explored revealing, for all 7 genes, a dose-dependent increase in gene expression with significant increases for individual genes beginning at 10 to 30 nmol/L (Figure 2A ). Two-way ANOVA comparing Aldo-stimulated fold changes for all 7 genes at all Aldo doses demonstrates a The GO Tree Machine was used to analyze the 72 Aldo-regulated genes. The highest level overrepresented category, the P value for overrepresentation, the associated gene list, and the Aldo-stimulated fold changes at each time point are listed. Fold changes with P Adj Ͻ0.05 are indicated in bold. BP indicates biological process; MF, molecular function; CC, cellular component. significant global increase in gene expression even at 1 nmol/L (Figure 2A , PϽ0.001, for 100, 30, and 10 nmol/L Aldo, and PϽ0.05 for 1 nmol/L Aldo, compared with vehicle and with all lower doses tested). These data support the idea that Aldo directly regulates vascular gene expression at physiological (1 nmol/L) and pathological (10 to 30 nmol/L) concentrations.
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Aldo-Regulated Vascular Gene Expression Requires Transcription but Not Translation
To explore the mechanism for the mRNA increase in response to Aldo, we examined Aldo-stimulated gene expres-sion after 1 hour of pretreatment with the transcriptional inhibitor actinomycin D or the translation inhibitor cycloheximide. Actinomycin D inhibited Aldo-stimulated increases in mRNA for all genes tested ( Figure 2B ; for PGF, see 19 ) supporting a transcriptional mechanism rather than mRNA stabilization. The enhanced transcription did not require new protein translation because it was not inhibited by cycloheximide ( Figure 2C , for PGF see 19 ). Thus, the signaling pathway components, transcription factors, and cofactors necessary for Aldo-stimulated transcription must already be present in the vessel.
Receptor, Hormone, and Cell Type Dependence of Aldo-Regulated Vascular Gene Expression
The receptor and hormone specificity of the vascular Aldoregulated genes was explored using MR and glucocorticoid receptor agonists and antagonists. Both spironolactone and the more receptor-selective MR antagonist eplerenone inhibited Aldo-stimulated gene transcription in the mouse aorta for all genes tested ( Figure 3A , Supplemental Figure I, and  Supplemental Table IV) , supporting an MR-dependent effect of Aldo. Cortisol (10 nmol/L) treatment resulted in only modest increases in expression of these 7 genes that were not significantly different from vehicle and were not affected by MR inhibition with either spironolactone ( Figure 3A ) or eplerenone (data not shown). In contrast, the same dose of Aldo significantly increased expression of several genes (Figure 2A ). It is notable that the modest increase in vascular expression of FKBP5 in the presence of cortisol was significantly inhibited by the glucocorticoid receptor antagonist RU486, supporting the idea that cortisol can activate glucocorticoid receptor in the vessel to regulate FKBP5 expression, as has been previously demonstrated in nonvascular cells. 27 These data support the idea that the gene expression changes we have identified in the vasculature are Aldo specific and vascular MR dependent under these conditions.
Mouse aortas consist predominantly of vascular SMC with smaller numbers of EC, fibroblasts, and resident immune cells. To explore the cell type in which these genes might be regulated, we treated primary mouse aortic SMC with Aldo for 8 hours and quantified expression of the same genes in SMC RNA. Aldo treatment of isolated SMC resulted in significant upregulation of all the genes tested with the exception of PGF ( Figure 3B , PGFϭ1.5-fold, Pϭ0.4). Overall, the pattern of the Aldo-stimulated changes was the same in isolated SMC, although the magnitude was less when compared with whole vessels (ie, FKBP5 had the greatest magnitude of Aldo regulation in all cases, but it was upregulated 5-to 10-fold in whole vessels [ Figure 2 and 3A] and only 3-to 4-fold in SMC). We saw no effect of Aldo on expression of these 7 genes in isolated EC under any conditions (data not shown). These data support the idea that SMC are sufficient for Aldo-stimulated regulation of most of these genes; however, the structure or cellular composition of the whole vessel may modulate the magnitude of the response.
A Subset of Aldo-Mediated Vascular Gene Regulation Is Enhanced in the Presence of Endothelial Damage and Is Free Radical Dependent
Animal studies and human clinical trials support the idea that Aldo promotes vascular disease in the setting of endothelial damage or dysfunction. We compared the Aldo-stimulated changes in gene expression in endothelium-denuded vessels (to mimic vascular damage) compared with endotheliumintact vessels. For all 7 genes tested, Aldo significantly enhanced gene expression in denuded vessels compared with vehicle ( Figure 4A , gray bars, PϽ0.05), further supporting the idea that these gene expression changes do not require the presence of EC. For a subset of the genes (PGF, MT1, and MT2), the Aldo-stimulated increase in mRNA was significantly greater in denuded vessels compared with intact vessels, supporting the idea that the normal endothelium attenuates Aldo-stimulated activation of this subset of genes. The Aldo effect on these 3 injury-enhanced genes was inhibited in the presence of the free radical scavenger Tempol ( Figure 4B ), implicating oxygen free radicals in the mechanism. For 2 additional genes, CTGF and FKBP5, Tempol treatment partially inhibited Aldo-activated gene transcription, and for BIRC2 and SGK, treatment with Tempol had no effect on Aldo-stimulated gene expression. These data demonstrate that Aldo, acting directly on MR in the blood vessel, regulates vascular gene expression via oxidative stress dependent and independent pathways.
Vascular oxidative stress is caused by production of free radicals by vascular oxidases and is mitigated by production of nitric oxide (NO), which inactivates free radicals. To begin to explore the mechanism for the oxidative stress-dependent Aldo-mediated gene expression changes, we examined Aldo regulation of the 5 genes that were inhibited by Tempol in the presence of the NADPH-oxidase inhibitor apocynin ( Figure  4C ) and the nitric oxide synthase inhibitor L-NMMA ( Figure  4D ) and in vessels from mice specifically deficient in eNOS ( Figure 4E) . Overall, the genes fell into 2 patterns, with Aldo regulation of MT1 and MT2 being relatively unaffected by NADPH-oxidase and NOS inhibition (only partial inhibition of MT2 regulation in eNOS-deficient vessels). For PGF, FKBP5, and CTGF, Aldo-stimulated gene expression was significantly attenuated in the presence of apocynin. Inhibition of NOS with L-NMMA resulted in significantly enhanced Aldo regulation of FKBP5, with a trend toward an increase for PGF and CTGF, and specific deletion of eNOS in the vessel resulted in enhanced Aldo regulation of both FKBP5 and CTGF, with a modest and nonsignificant trend for PGF. These data support a role for NADPH-oxidase in promoting Aldo upregulation of a specific subset of genes with a contribution of NOS, perhaps from ECs, in attenuating this effect.
Enhanced Expression of Hemodynamically Regulated Genes in Atherosclerosis-Prone Aortic Segments Exposed to Aldo
Although atherosclerosis is a diffuse disease of the vasculature, there is a predisposition for lesion formation at vascular branch points and other areas of turbulent blood flow. 28 Thus, we compared Aldo-stimulated gene expression in the atherosclerosis-prone aortic arch, an area exposed to nonlaminar (proatherogenic) blood flow, compared with the descending aorta, an area of laminar flow and decreased atherosclerotic burden. 28 For all 7 genes, Aldo treatment increased mRNA expression in both the arch and descending aorta ( Figure 5A ). Interestingly, for the 3 genes with enhanced Aldo regulation in the setting of endothelial injury (PGF, MT1, MT2), we also found a significant increase in the magnitude of expression in the Aldo-exposed aortic arch compared with the Aldo- exposed descending aorta. A small group of genes (including PGF, MTs, and CTGF) has been previously identified to be upregulated in cultured vascular cells by proatherogenic hemodynamic flow. 29 We compared gene expression levels for this subset of hemodynamically regulated genes to the genes not induced by atherosclerosis-prone flow (FKBP5, SGK, BIRC2) by 3 factor ANOVA (comparing flowdependence, vessel segment, and Aldo treatment). There is a significant increase in expression of the atherosclerosis-prone flow genes in both vehicle-and Aldo-treated aortic arch segments compared with the descending aorta (PϽ0.05). This is not the case for the genes unaffected by atherosclerosis-prone flow. MR message expression was the same in the arch and descending aorta, supporting the idea that differences in Aldoregulated gene expression in these segments are not mediated by changes in MR message. This finding supports a potential novel role for Aldo in the mechanism underlying the nonuniform distribution of atherosclerotic lesions in the vasculature.
MR-Mediated Gene Regulation in Atherosclerotic Human Vessels
We next explored whether the MR-regulated vascular genes we identified in mouse aortas might also be regulated by MR in human vessels. Aortic punches removed from patients undergoing coronary artery bypass graft surgery were treated ex vivo with spironolactone (1 mol/L) for 18 hours followed by RNA isolation. In human aortic samples, treatment with MR antagonist resulted in a 40% to 80% reduction in mRNA for all 7 genes tested ( Figure 5B ; for PGF, see 19 ). These data support the idea that the MR-regulated vascular genes identified in mouse vessels using this transcriptional profiling method are also regulated by vascular MR in diseased human vessels and are downregulated by the clinically beneficial MR antagonist spironolactone and thus could play a role in the mechanisms of vascular protection by MR-antagonist drugs in clinical trials.
Discussion
This study examined the immediate effects of the hormone Aldo on vascular gene expression programs in whole blood vessels and explored the molecular mechanism of Aldoregulated gene expression for a subset of these genes. The data demonstrate that (1) Aldo rapidly and directly regulates vascular gene expression; (2) vascular Aldo-regulated genes are overrepresented in GO categories related to vascular function and disease; (3) for those genes tested, vascular gene expression is regulated by Aldo but not cortisol at clinically relevant concentrations via a vascular MR-dependent transcriptional mechanism; (4) for a subset of genes tested, Aldo-stimulated expression is enhanced in the presence of endothelial damage and is free-radical dependent with a contribution from NADPH oxidases and protection by NOS; (5) in segments of the vessel prone to atherosclerosis, Aldo further enhances expression of a subset of genes that has been implicated in promoting atherosclerosis under nonlaminar flow conditions; and (6) MR antagonists inhibit expression of these genes in human vessels from patients with atherosclerosis. This study identifies direct effects of Aldo-activated vascular MR on vascular gene expression that may contribute to the detrimental vascular effects of this hormone, explores the molecular mechanisms for these vascular gene regulatory effects, and begins to address the mechanism for the vascular protective effects of MR antagonists in human clinical trials.
It has recently become clear that MR in human vascular cells can directly regulate gene transcription, 9, 10 raising the possibility that vascular MR-regulated genes could mediate the effects of Aldo on vascular physiology and disease in humans. Indeed, our further exploration of PGF, one of the vascular MR-regulated genes identified from this profiling study, demonstrated a critical role for PGF in Aldo-mediated vascular injury in vivo, 19 supporting the idea that this method has identified pathways that are important in the biology of Aldo-induced vascular dysfunction in vivo. Thus, by identifying the early Aldo-regulated transcriptome in whole vessels, this study provides an important resource to further explore mechanisms of mineralocorticoid-mediated vascular dysfunction and may provide novel drug targets to prevent or treat vascular disease in humans.
The trend for very early steroid-mediated gene repression followed by induction over time is consistent with recent RNA expression profiles from hearts of Aldo-injected mice, 16 estrogen-treated breast cancer cells, 25 and our recent study in estrogen-treated vessels. 23 In addition, the pattern of rapid repression of distinct genes after 2 hours of hormone treatment followed by overlapping gene upregulation cascades at 4 and 8 hours is similar to the pattern of estrogen-regulated genes in the vasculature, 23 supporting the potential for common mechanisms to mediate this pattern of steroid-mediated vascular gene regulation. Aldo can modulate gene expression by direct, so-called "genomic," effects mediated by MR binding to DNA and by "nongenomic" mechanisms, mediated by activation of cytoplasmic signaling pathways that regulate other transcription factors. We have found an Aldoregulated MR binding site in the PGF upstream DNA region 19 as well as in intron E of the FKBP5 gene (data not shown), a site that has previously been shown to mediate regulation of FKBP5 by other steroid receptors. 26 Future computational and experimental analyses are warranted to explore the contributions of genomic and nongenomic signaling mechanisms to the global regulation of vascular genes by Aldo.
Several vascular genes identified in this study were already known to be regulated by Aldo in other tissues, including SGK, a known MR target in the kidney, and CTGF, which is regulated by mineralocorticoids in the kidney and heart. 30 SGK and CTGF play a role in Aldo-mediated renal and cardiac fibrosis 30, 31 ; thus, the finding that these genes are regulated by vascular MR supports a potential new mechanism for Aldo-mediated vascular fibrosis that can be further explored in vivo. FKBP5 is known to be regulated by several steroid hormones in nonvascular cells, 26 but its regulation in the vasculature by Aldo and MR has not been previously reported. A few of the vascular Aldo-regulated genes identified here overlap with Aldo-regulated genes identified by profiling of MR-expressing cardiomyocytes, 15 including AD-AMTS1, FKBP5, SGK, and AKAP12. However, the majority of Aldo-regulated vascular genes identified in this study are distinct from genes regulated by Aldo in the heart 16 and in other tissues, supporting tissue-specific effects of Aldo and MR in the vasculature.
In animal models, Aldo promotes vascular inflammation, 17 vascular remodeling after injury, 18 and atherosclerosis. 20 Although several mRNAs and proteins are increased in vascular tissues in these models, the mechanisms underlying these expression changes are not known. Using an ex vivo Aldo treatment approach, we can conclude that the gene expression changes observed are due to direct effects of Aldo on the vessel rather than to vascular responses that may be secondary to Aldo effects in other tissues, particularly the kidney and heart, which have confounded interpretations of Aldo effects on the vasculature in the past. Inhibition of the Aldo-stimulated effects by actinomycin D and MR antagonists in this study supports a vascular MR-mediated transcriptional mechanism, and the lack of regulation by cortisol supports Aldo as the vascular MR ligand under these conditions.
In this study, we identified a number of genes with established roles in vascular function and disease that have not been previously known to be regulated by Aldo in the vasculature. CTGF has been shown by several groups to be upregulated in diseased human vessels and is implicated in vascular remodeling, dissection, atherosclerotic lesion development, and plaque rupture. CTGF regulates SMC proliferation, migration and production of collagen extracellular matrix, vascular cell apoptosis, matrix metalloproteinase expression, and inflammatory cell recruitment (reviewed in 32 ). The metallothioneins are metal binding proteins that are upregulated in response to oxidative stress in nonvascular cells, where they protect from apoptosis and inflammation. 33 The in vivo role of MT in protection from oxidative stress is more controversial. 33 Regulation of this family of genes by Aldo has not been previously reported, and the role of this regulation in vascular function deserves further study. PGF is a proangiogenic and proinflammatory growth factor that promotes vascular cell proliferation and monocyte chemotaxis. We have recently further explored Aldo regulation of PGF and demonstrated that Aldo enhances vascular PGF protein expression and secretion and that PGF plays a role in vivo in Aldo-stimulated vascular remodeling after injury. 19 By enhancing expression of genes that promote inflammation (PGF, CTGF), increasing expression of matrix proteases that degrade the fibrous cap of atherosclerotic lesions (AdamTS1, CTGF), and decreasing expression of inhibitors of matrix metalloproteinases (TIMP3), Aldo may destabilize atherosclerotic plaques and vessel integrity, thereby promoting myocardial infarction, stroke, and aortic dissection. Additional in vivo animal and clinical studies will be necessary to test these hypotheses.
The finding that a subset of vascular genes demonstrates enhanced upregulation by Aldo in vessels with endothelial damage is consistent with the hypothesis that the endothelium inhibits Aldo-stimulated expression of these genes in healthy vessels, perhaps by production of NO, and that this protection may be lost in disease states that cause EC dysfunction or injury. This hypothesis could provide a novel explanation for the conundrum that in mouse models, Aldo alone does not promote vascular damage without the concomitant presence of some form of endothelial damage or dysfunction. [17] [18] [19] [20] Indeed, in human trials, the cardiovascular protective effects of drugs that block Aldo production or MR activation, are evident in patients with normal or elevated serum Aldo levels in the setting of cardiovascular risk factors that can produce endothelial dysfunction, including patients with heart failure, 1 coronary artery disease, 2 diabetes, 4 or other cardiovascular risk factors. 4 In this study, treatment of vessels with the superoxide dismutase-mimetic Tempol (which would be expected to decrease the abundance of oxygen radicals and peroxynitrite) attenuated Aldo activation of this same subset of genes (along with several others), supporting a synergistic role for vascular oxidative stress and vascular MR activation in regulating a subgroup of vascular Aldo target genes. Aldo is known to increase reactive oxygen species production in vascular cells by several mechanisms, including enhanced NADPH oxidase expression and activity. 10, 34, 35 Treatment of vessels with the NADPH-oxidase inhibitor apocynin significantly attenuated the Aldo-mediated regulation of only a subgroup of the reactive oxygen species-dependent MRregulated genes supporting a role for NADPH oxidase, as well as other oxidases, in this mechanism. Vessel wall shear stress also induces reactive oxygen species generation 36 and hence may play a role in mediating the differential affects of Aldo on gene expression in aortic segments subjected to different flow conditions as in Figure 5A . Synergism between MR activation and oxidative stress has been shown to play a role in other pathological effects of mineralocorticoids, including renal and cardiac fibrosis, 37 vascular remodeling, 38 and atherosclerosis. 20 The oxidative stress-dependent, Aldo-regulated vascular genes identified in this study overlap significantly with a small group of 11 genes (including PGF, MTs, and CTGF) that have been implicated in atherogenesis because of their induction by blood flow patterns present in atherosclerosisprone areas of the carotid artery and downregulation by atheroprotective blood flow. 29 We found increased expression of this subgroup of genes in the atherosclerosis-prone aortic arch in both vehicle and Aldo-treated vessel segments compared with the relatively atherosclerosis-protected descending aorta. These data support the hypothesis that endothelial damage and vascular oxidative stress, mediated by cardiac risk factors or hemodynamic forces, synergize with vascular MR activation by Aldo to enhance expression of a particularly proatherogenic group of genes. This mechanism could also play a role in the proatherogenic effects of torcetrapib that correlated with off-target increases in serum Aldo [5] [6] [7] and may play a role in the protective effects of MR antagonists in cardiovascular patients. 1, 2 Several limitations and areas of further study are worth noting. We chose to profile gene expression in whole vessels (rather than cultured cells) because vascular cell function is known to be regulated by complex paracrine signaling between distinct cell types in the vasculature, 39 and we believe this strategy would therefore yield more biologically relevant genes. However, the use of whole vessels makes it difficult to precisely determine the cell type in which Aldo regulation is occurring. Overall, because SMC make up the majority of the murine vessel, many of the gene regulatory effects could be recapitulated in isolated SMC, and gene regulation by Aldo was preserved under the denuded vessel conditions, changes in mRNA abundance likely represent predominantly SMC effects. The decreased magnitude of the Aldo effect in cultured SMC could be due to the separation of the SMC from other contributing cell types but could also be due to differences in the experimental techniques. Activation of endothelial MR likely regulates other genes (such as intracellular adhesion molecule 1, which we have previously demonstrated to be MR regulated in human coronary EC 10 ) that would therefore be unlikely to be identified in this study because of the small contribution of EC to total vascular mRNA. However, although the cell number and RNA contribution is small, a paracrine contribution due to MR activa-tion in EC, vascular fibroblasts, and inflammatory cells could contribute to SMC gene expression. Indeed, the enhanced regulation of a subset of genes by Aldo in the absence of the endothelium supports that multiple cell types interact to determine the ultimate magnitude of the transcriptional responses to Aldo in the vessel. In addition, MR in inflammatory cells, including macrophages, has recently been shown to modulate cardiovascular outcomes in animal models 40 ; thus, the role of immune cell MR in regulation of vascular gene expression deserves further study. We also chose an ex vivo hormone treatment approach (rather than in vivo infusion or injection) to identify direct vascular MR target genes and to limit the secondary vascular effects of in vivo MR activation in nonvascular tissues. However, removal of the vessel from the animal eliminates the interaction of the vessel with pulsatile and shear hemodynamic forces, as well as other circulating factors that may contribute to vascular gene expression and may modulate the response to Aldo. This limitation is controlled for by comparing mRNA expression in Aldo-treated vessels to that in vessels removed for the same amount of time and treated in an identical fashion with vehicle. The degree to which removal of the vessel modifies basal gene expression over time could be further explored in the vehicle-treated expression data over time. However, the finding of increased basal expression of genes previously known to be responsive to hemodynamic shear forces 29 in the aortic arch compared with the descending aorta supports the idea that at these short time points, there is some "memory" in the vessel for the hemodynamic and shear forces to which it was previously exposed in vivo. Further investigation using in vivo models will be needed to put these direct vascular Aldo target genes into the context of whole animal physiology.
In summary, we have explored the early Aldo-regulated vascular transcriptome and identified vascular genes directly and transcriptionally regulated by Aldo-activated vascular MR. We have further characterized a subset of proatherogenic genes with enhanced Aldo-stimulated, oxidative stressdependent expression in the setting of vascular injury and in areas predisposed to atherosclerosis. We have further established that expression of these genes is inhibited in diseased human vessels by treatment with vascular protective MR antagonist drugs. These data support a novel mechanism for vascular disease in which vascular MR acts synergistically with endothelial injury and oxidative stress to upregulate proatherogenic genes in atherosclerosis-prone vascular regions. Further exploration of the role of these novel MRregulated genes in the pathophysiology of vascular disease will help elucidate the mechanism of the protective effects of Aldo antagonists in patients with endothelial dysfunction and provide novel drug targets to prevent cardiovascular ischemic events in humans.
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